| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer … DH Henry, L Costa, F Goldwasser, V Hirsh, V Hungria, J Prausova, ... Journal of Clinical Oncology 29 (9), 1125-1132, 2011 | 1457 | 2011 |
| Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ... The lancet oncology 14 (1), 29-37, 2013 | 1409 | 2013 |
| The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network CJ Voskens, SM Goldinger, C Loquai, C Robert, KC Kaehler, C Berking, ... PloS one 8 (1), e53745, 2013 | 504 | 2013 |
| Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer G Fürstenberger, R Von Moos, R Lucas, B Thürlimann, HJ Senn, ... British journal of cancer 94 (4), 524-531, 2006 | 286 | 2006 |
| Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with … D Henry, S Vadhan-Raj, V Hirsh, R Von Moos, V Hungria, L Costa, ... Supportive Care in Cancer 22, 679-687, 2014 | 215 | 2014 |
| Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study F Strasser, TA Lutz, MT Maeder, B Thuerlimann, D Bueche, M Tschöp, ... British journal of cancer 98 (2), 300-308, 2008 | 200 | 2008 |
| Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib M Montemurro, P Schöffski, P Reichardt, H Gelderblom, J Schütte, ... European journal of cancer 45 (13), 2293-2297, 2009 | 186 | 2009 |
| Pegylated liposomal doxorubicin-associated hand–foot syndrome: recommendations of an international panel of experts R Von Moos, BJK Thuerlimann, M Aapro, D Rayson, K Harrold, J Sehouli, ... European journal of cancer 44 (6), 781-790, 2008 | 181 | 2008 |
| Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double‐blind study of denosumab and zoledronic acid CS Cleeland, JJ Body, A Stopeck, R Von Moos, L Fallowfield, SD Mathias, ... Cancer 119 (4), 832-838, 2013 | 169 | 2013 |
| Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma Y Waeckerle-Men, E Uetz-von Allmen, M Fopp, R von Moos, C Böhme, ... Cancer Immunology, Immunotherapy 55, 1524-1533, 2006 | 160 | 2006 |
| Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non … D Koeberle, DC Betticher, R Von Moos, D Dietrich, P Brauchli, ... Annals of oncology 26 (4), 709-714, 2015 | 154 | 2015 |
| Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical … M Borner, D Koeberle, R Von Moos, P Saletti, D Rauch, V Hess, A Trojan, ... Annals of oncology 19 (7), 1288-1292, 2008 | 152 | 2008 |
| Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results … X Pivot, A Schneeweiss, S Verma, C Thomssen, JL Passos-Coelho, ... European journal of cancer 47 (16), 2387-2395, 2011 | 143 | 2011 |
| Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 … S Kubicka, R Greil, T André, J Bennouna, J Sastre, E Van Cutsem, ... Annals of oncology 24 (9), 2342-2349, 2013 | 134 | 2013 |
| Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study S Borgquist, A Giobbie-Hurder, TP Ahern, JE Garber, M Colleoni, I Láng, ... Journal of clinical oncology 35 (11), 1179-1188, 2017 | 131 | 2017 |
| Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial … T Ruhstaller, M Pless, D Dietrich, H Kranzbuehler, R von Moos, ... Journal of clinical oncology 29 (6), 626-631, 2011 | 131 | 2011 |
| The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster … F Strasser, D Blum, R Von Moos, R Cathomas, K Ribi, S Aebi, D Betticher, ... Annals of Oncology 27 (2), 324-332, 2016 | 129 | 2016 |
| Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment A Glaus, CH Boehme, B Thürlimann, T Ruhstaller, SFH Schmitz, R Morant, ... Annals of oncology 17 (5), 801-806, 2006 | 124 | 2006 |
| Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of … D Arnold, T Andre, J Bennouna, J Sastre, PJ Osterlund, R Greil, ... Journal of Clinical Oncology 30 (18_suppl), CRA3503-CRA3503, 2012 | 123 | 2012 |
| Improving quality of life in patients with advanced cancer: targeting metastatic bone pain R von Moos, L Costa, CI Ripamonti, D Niepel, D Santini European journal of cancer 71, 80-94, 2017 | 122 | 2017 |
Richard CathomasOnkologie/Hämatologie Kantonsspital GraubündenVerificeret mail på ksgr.ch